Skip to content
Axe Capital logo Axe Capital Trading News

Axe Capital Investments

Clear market notes built around the JSE, the rand, and what matters locally.

Axe Capital Trading News shares simple market takes on the stories moving South African shares, the rand, and a handful of major currency pairs.

What you will find here:

1. JSE shares, South African companies, and the local knock-on effects of big market news.

2. The rand, interest rates, and a small group of forex pairs, with USD/ZAR at the centre.

3. Global stories only when they can actually change how a local investor might act.

Latest market stories

Why Sally Beauty Stock Popped Today
2026-08-03 22:20 The Motley Fool Positive Axe Cap view: Selective

Sally Beauty Holdings reported progress in its turnaround strategy with net sales up 0.2% to $935 million in Q3, comparable sales growth of 1.6%, and strong e-commerce performance with online sales up 11%. The company improved profit margins, generated $62 million in free cash flow, and increased adjusted EPS by 8% to $0.55. Management projects full-year sales of $3.7 billion and EPS of $2.04-$2.08, with plans to expand into new categories like fragrances and men's products.

Axe note: Strong Q3 results and e-commerce growth fuel optimism in Sally Beauty’s recovery.

Investing in the "Magnificent Seven?" Pick Your Poison: Negative Free Cash Flow or an Unjustifiable Valuation.
2026-08-03 22:06 The Motley Fool Negative Axe Cap view: Selective

The Magnificent Seven tech giants face a critical dilemma in 2026: companies aggressively investing in AI infrastructure report negative free cash flow, while those maintaining normal capex levels trade at unsustainable valuations. Most underperformed the S&P 500 year-to-date, with only Apple outperforming, leaving investors to choose between betting on AI-driven growth or accepting inflated valuations.

Axe note: Tech giants face a tough 2026 choice—bet heavily on AI with negative cash flow or stay expensive and underdeliver.

Why Supernus Pharmaceuticals Stock Topped the Market Today
2026-08-03 22:05 The Motley Fool Mixed Axe Cap view: Selective

Supernus Pharmaceuticals announced a merger with Indivior Pharmaceuticals in an all-stock deal, creating a combined company with 11 FDA-approved drugs and anticipated $125 million in annual cost synergies. The stock rose 3% despite initial gains of 16%, reflecting cautious optimism. Q2 earnings showed 32% revenue growth to $219 million but a net loss of $58 million, missing earnings estimates while beating revenue forecasts.

Axe note: A US pharma merger lifts shares but offers limited direct impact for JSE investors.

What we follow

We keep the focus on JSE shares, the rand, and the currency moves that matter most to South African investors.

JSE and rand